pulmonary arterial hypertension
NICE recommends sotatercept for pulmonary arterial hypertension
May 20, 2026NICE, Winrevair, pulmonary arterial hypertension, sotatercept
The National Institute for Health and Care Excellence (NICE) has recommended Winrevair (sotatercept) as a treatment option for adults with …
Tiakis Biotech appoints Christoph Schmidt to supervisory board
May 22, 2025Research and Development Cardiology, Tiakis Biotech, cardiovascular diseases, pulmonary arterial hypertension
Tiakis Biotech has announced the appointment of Christoph Schmidt to its supervisory board. Based in Kiel, Germany, the clinical-stage biotech …
FDA approves Merck’s Winrevair for PAH treatment
March 27, 2024Medical Communications Cardiology, FDA, Merck, Winrevair, pulmonary arterial hypertension
Merck, known as MSD outside of the US and Canada, has announced that the US Food and Drug Administration (FDA) …
FDA approves J&J’s Opsynvi for PAH treatment
March 25, 2024Medical Communications Cardiology, FDA, J&J, Johnson & Johnson, Opsynvi, pulmonary arterial hypertension
Johnson & Johnson (J&J) has announced that the US Food and Drug Administration (FDA) has approved Opsynvi (macitentan and tadalafil) …
United Therapeutics terminates oral pulmonary arterial hypertension drug following Phase 3 failure
April 9, 2019Manufacturing and Production, Research and Development Tyvaso, United Therapeutics, pharma, pulmonary arterial hypertension
United Therapeutics has revealed in a short announcement that, because its pulmonary arterial hypertension (PAH) therapy failed to meet its …
Actelion’s Uptravi and rare bleeding disorder drug get positive EMA decisions
February 1, 2016Sales and Marketing CHMP, EMA, Uptravi, pulmonary arterial hypertension, selexipag
The Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the EMA, has issued positive opinions on …
Actelion’s Uptravi goes on sale
January 5, 2016Manufacturing and Production, Sales and Marketing Actelion, PAH, Uptravi, pulmonary arterial hypertension, pulmonary hypertension, selexipag
Swiss pharma firm Actelion has put its new drug for pulmonary hypertension, Uptravi, up for sale in the US, weeks …
Actelion ready to launch Uptravi after FDA approval
December 22, 2015Research and Development, Sales and Marketing Actelion, FDA, Jean-Paul Clozel, Uptravi, pulmonary arterial hypertension, selexipag
Actelion says it is ready to launch Uptravi, its drug for pulmonary arterial hypertension in the US in January, after …
Pfizer’s Revatio extends Europe PAH licence
May 9, 2011Sales and Marketing PAH, Pfizer, pulmonary arterial hypertension, revatio
Pfizer’s Revatio has been approved by European regulators for the treatment of pulmonary arterial hypertension (PAH) in children.The European Commission has …
Pfizer withdraws hypertension drug Thelin
December 14, 2010Sales and Marketing PAH, Pfizer, Thelin, liver damage, liver toxicity, patient safety, pulmonary arterial hypertension, sitaxentan
Pfizer has suffered a blow to its drug development programme with the withdrawal of pulmonary arterial hypertension (PAH) brand Thelin …
